What is Incyte Corporation (INCY) DCF Fair Value and Intrinsic Value in 2026?

Incyte Corporation (INCY) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is Incyte Corporation's historical Return on Invested Capital (ROIC) and Moat Rating?

Incyte Corporation operates in the Healthcare sector (Biotechnology) with an economic moat rating of NARROW. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is Incyte Corporation's financial health rating and Piotroski F-Score?

Incyte Corporation's balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor Incyte Corporation (INCY) for quarterly SEC filing thesis breaks?

LocalAlpha audits Incyte Corporation's 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksINCY

INCY

Incyte CorporationHealthcare / BiotechnologyINTACT

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Share Price

$121.47

52W: $81.09 - $132.6

DCF Fair Value

$208.26

+41.7% MoS

Thesis Hub

P/E (TTM)

15.5x

ROIC

31.4%

Operating Margin

41.9%

FCF Yield

4.8%

Debt / Equity

0.01x

Piotroski Score

8/9

Altman Z-Score

3.73

Market Cap

$24.6B

Price vs. Intrinsic Value Corridor

Margin of Safety Buy Zone (<25% Discount)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$208.26

MOS Buy Target (-25%)

$156.20

Valuation Overlays: DCF Fair Value ($208.26) 25% MOS Buy Target ($156.20) Revised Graham ($277.04) Graham Number ($74.67)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$121.47

DCF Fair Value

$207.97

+41.6% MoS

Starting Free Cash Flow ($M)$1,181M

$100M$1,181M (Reported)$50,000M

Stage 1 Growth (Years 1-5)18.0%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)-$4,500M (Net Cash)

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$15.3B

PV of Terminal Value

$22.4B

Implied Enterprise Value

$37.7B

Implied Equity Value

$42.2B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$1,394	$1,644	$1,940	$2,290	$2,702	$2,823	$2,950	$3,083	$3,222	$3,367
Present Value (PV)	$1,279	$1,384	$1,498	$1,622	$1,756	$1,684	$1,614	$1,547	$1,484	$1,422

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-62.7% Premium

$74.67

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $7.85BVPS: $31.57

Revised Graham Formula+56.2% MoS

$277.04

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings4.6% Yield

$5.53 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $1.1BYield: 4.6%

Reverse DCF: Market Growth Expectation

MODEST BARRIER

6.2% CAGR (Next 10 Yrs)

At the current price of $121.47, the market is assuming the business will compound Free Cash Flow at 6.2% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

✓ Low market hurdle: Easy for a wide-moat compounder to beat.

Autonomous Thesis Underwriting

Surveil INCY with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for Incyte Corporation. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 41.9% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track INCY & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: Incyte Corporation (INCY) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Incyte Corporation.

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, Incyte Corporation has an estimated DCF intrinsic fair value of $208.26 per share compared to its current market price of $121.47. This represents an estimated 41.7% margin of safety (trading below fair value). Additionally, its classic Benjamin Graham Number stands at $74.67.